Atovaquone
SIGMA/A7986 - ≥98% (HPLC)
Synonym: Mepron; trans-
CAS Number: 95233-18-4
Empirical Formula (Hill Notation): C22H19ClO3
Molecular Weight: 366.84
Linear Formula: C22H19ClO3
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | yellow |
| form | powder |
| InChI | 1S/C22H19ClO3/c23-16-11-9 |
| InChI key | KUCQYCKVKVOKAY-CTYIDZIISA |
| originator | GlaxoSmithKline |
| Quality Level | 100  |
| SMILES string | OC1=C([C@H]2CC[C@@H](CC2) |
| solubility | DMSO: >10 mg/mL |
| storage temp. | −20°C |
| Application: | Atovaquone inhibits the cytochrome bc(1) complex via interactions with the Rieske iron-sulfur protein and cytochrome b in the ubiquinol oxidation pocket. In addition to its use as a treatment for toxoplasmosis, atovaquone has antimalarial properties and prevents pneumocystis pneumonia post-renal transplant. |
| Biochem/physiol Actions: | Atovaquone is an anti-protozoal mitochondrial electron transport inhibitor; Antimalarial; Antipneumocystic, and has also been used to treat toxoplasmosis. It is an analog of protozoan mitochondrial protein ubiquinone, and acts by inhibiting the cytochrome bc(1) complex via interactions with the Rieske iron-sulfur protein and cytochrome b in the ubiquinol oxidation pocket. |
| Features and Benefits: | This compound was developed by GlaxoSmithKline . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 10, 50 mg in glass bottle |
| Hazard Codes | N |
| Risk Statements | 50/53 |
| Safety Statements | 60-61 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |